Perbak Capital Partners LLP Ionis Pharmaceuticals Inc Transaction History
Perbak Capital Partners LLP
- $568 Billion
- Q3 2025
A detailed history of Perbak Capital Partners LLP transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Perbak Capital Partners LLP holds 4,426 shares of IONS stock, worth $316,680. This represents 0.05% of its overall portfolio holdings.
Number of Shares
4,426
Previous 9,538
53.6%
Holding current value
$316,680
Previous $377 Million
23.17%
% of portfolio
0.05%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding IONS
# of Institutions
507Shares Held
155MCall Options Held
2.69MPut Options Held
1.03M-
Vanguard Group Inc Valley Forge, PA16.5MShares$1.18 Billion0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD13.2MShares$941 Million0.53% of portfolio
-
Capital World Investors Los Angeles, CA12.7MShares$910 Million0.12% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$738 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.59MShares$471 Million0.08% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $10.2B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...